Adibah Hanis Zainudin1*, Bee Tee Koay1, Jamiila Ismail1, Zurina Shamsuddin1, Salawati Mansor1, Asmadamia Abdul Aziz1, Masita Arip2, Norhazlin Mustafa1
1. Transplantation Immunology Unit, Allergy and Immunology Research Centre (AIRC), Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health, Malaysia, 40170 Shah Alam, Selangor, Malaysia
2. Allergy and Immunology Research Centre (AIRC), Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health, Malaysia, 40170 Shah Alam, Selangor, Malaysia
*Corresponding author: Adibah Hanis Zainudin.
ABSTRACT
INTRODUCTION: Carbamazepine, a routinely prescribed antiepileptic medication, has been linked to severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), among people who carry the HLA-B*15:02 allele. However, new data suggest that other HLA-B alleles may be potentially involved in carbamazepine-induced cutaneous hypersensitivity reactions.
OBJECTIVE(S): The purpose of this study is to explore the frequencies of HLA-B alleles other than HLA-B*15:02 among patients who have developed SJS or other cutaneous reactions after taking carbamazepine, and to see if less often recognised alleles are relevant.
MATERIALS & METHODS: A total of 2,781 patient samples were received by the Transplantation Immunology Laboratory IMR from hospitals in Malaysia between January 2022 and December 2024 for HLA-B*15:02 disease association. Samples were sent either prior to carbamazepine initiation or after the development of skin rashes post carbamazepine exposure. HLA-B allele identifications were performed using Sequence-Specific Oligonucleotide (SSO) hybridisation.
RESULTS: Of 2,778 patient samples, 457 (16.5%) were positive for HLA-B*15:02, while 2,321 (83.5%) were negative. Among the negative group, 32 cases showed clinical signs of drug-induced rash. These patients carried other alleles, such as HLA-B*15:13 and HLA-B*15:21, that has been shown to cause drug hypersensitivity. Their presence suggests possible genetic links to carbamazepine-induced severe cutaneous adverse reactions, particularly SJS.
CONCLUSION: While HLA-B*15:02 remains the primary allele of concern in carbamazepine hypersensitivity, our findings suggest that HLA-B*15:13 and HLA-B*15:21 may also contribute to adverse reactions. Further studies are necessary to clarify their clinical significance and consider their inclusion in pharmacogenetic screening strategies.
KEYWORDS: Carbamazepine, Stevens-Johnson Syndrome, Pharmacogenomics, HLA-B*15:02, Disease Association


